Diamyd Medical deepens long-term manufacturing collaboration for retogatein

Diamyd Medical is taking the next step in a long-term manufacturing collaboration with APL and, in parallel, is initiating a strategic collaboration with NorthX Biologics to further develop and scale the manufacturing of retogatein (rhGAD65) ahead of commercialization.“This is a natural next step in work that has been built up over time,” says Ulf Hannelius, CEO of Diamyd Medical. By combining Diamyd Medical’s in-house drug substance manufacturing with APL’s long-standing fill and finish expertise and now adding the validation capabilities of NorthX Biologics, we are creating a sustainable